A platelet bioreactor was developed by researchers at Brigham and Women's Hospital.
The psychiatric sector received a big boost this week when the Broad Institute was given $650 million to investigate the genetic causes of mental illnesses such as schizophrenia and bipolar disorder. And the impact of the work is set to extend far beyond Cambridge, with Broad making the data available to researchers around the world.
The rise of electronic health records was heralded as a step toward the merging of patient care and research, a scenario in which data from the day-to-day of healthcare is gathered to inform treatment and drug development. But a study in the United Kingdom suggests that while technology can now facilitate this vision, the path is blocked by another barrier: red tape.
The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
A new three-drug combo treatment for tuberculosis better eradicated the disease than standard therapy in a midstage trial, showing particular promise for patients with HIV as it rolls into Phase III development.
Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.
Patient monitoring technology is a growing niche within the industry, with big and small operations looking for their cut of the profits. A new device from a team of nurses, engineers and computer scientists takes the trend one step further, monitoring a patient's health through a bandage.
Scientists from the Broad Institute are unveiling new genomic findings from thousands of schizophrenia patients that could lead to new molecular targets. And, thanks to the philanthropist Ted Stanley, they'll have $650 million to help find out.
This morning Atlas Venture and New Enterprise Associates announced that they have committed $29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially seeded last fall that has set out to build a platform that can create therapeutic microbes.
Baltimore-based Cerecor has gathered up the first half of a $33 million B round, with plans to devote much of that money to a midstage development program for an experimental depression therapy recently punted by a restructuring Merck.